Toshiya Nishi

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

KCC2 Activation Reverses Neurophysiological and Behavioral Deficits in Female Rett Mice.

KCC2 Activation Reverses Neurophysiological and Behavioral Deficits in Female Rett Mice.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

KCC2 activation during postnatal development alleviates long-term deficits in CDKL5-deficient mice.

KCC2 activation during postnatal development alleviates long-term deficits in CDKL5-deficient mice.

Journal: Experimental & molecular medicine

Published: June 08, 2025

Structure-based design of a novel series of cholesterol 24-hydroxylase (CH24H) inhibitors bearing 1,3-oxazole as a heme-iron binding group.

Structure-based design of a novel series of cholesterol 24-hydroxylase (CH24H) inhibitors bearing 1,3-oxazole as a heme-iron binding group.

Journal: Bioorganic & medicinal chemistry

Published: May 16, 2025

Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors.

Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: March 12, 2025

Activation of KCC2 during development alleviates cognitive, behavioral, and neural excitability in adult CDKL5-deficient mice.

Activation of KCC2 during development alleviates cognitive, behavioral, and neural excitability in adult CDKL5-deficient mice.

Journal: bioRxiv : the preprint server for biology

Published: March 10, 2025

Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models.

Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models.

Journal: Neuroscience research

Published: March 15, 2024

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice.

Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice.

Journal: Neuropharmacology

Published: July 27, 2022

Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H).

Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H).

Journal: European journal of medicinal chemistry

Published: June 06, 2022

Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy.

Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy.

Journal: Neurobiology of disease

Published: April 06, 2022

Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.

Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.

Journal: Journal of medicinal chemistry

Published: February 15, 2022

Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor.

Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor.

Journal: Epilepsia

Published: December 23, 2021

Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H).

Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H).

Journal: Journal of medicinal chemistry

Published: August 13, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026